• 19.03.2019 – 09:01

  Nyxoah S.A

  Nyxoah Receives European CE Mark Approval for the Genio® System, a Disruptive Neurostimulation Solution for Obstructive Sleep Apnea Therapy

  Mont-Saint-Guibert, Belgium (ots/PRNewswire) - Nyxoah S.A., a healthtech company focusing on the development of innovative solutions and services for sleep related disorders, today announced that the company has received CE Mark approval for the Genio® system in Europe. The Genio® system is the world's first and ...

  more

• 29.01.2019 – 15:37

  Kanabo Research

  Lights Out for Insomnia: New Kanabo Research Study Offers Encouraging Results

  Tel Aviv, Israel (ots/PRNewswire) - Kanabo Research is proud to present the promising results of its pre-clinical trial, which brings the company one step closer to providing a safe remedy for insomnia and other sleep disorders, without the risk of dependency or the possibility of an overdose. (Photo: ...

  more

• 12.11.2018 – 12:01

  Nyxoah S.A

  Nyxoah Raises EUR15 Million in New Financing, Completes BLAST OSA Clinical Study

  Mont-Saint-Guibert, Belgium (ots/PRNewswire) - Nyxoah S.A., a medical device company focused on the development and commercialization of a best-in-class hypoglossal nerve stimulation (HGNS) therapy for the treatment of Obstructive Sleep Apnea (OSA), announced today that it successfully raised an additional EUR15 million ($17.1 million USD) in their most recent round of ...

  more